Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Yakugaku Zasshi ; 128(9): 1311-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18758145

ABSTRACT

Peptide YY (PYY) is produced by endocrine cells in the lower gastrointestinal tract. The main functions of PYY are antisecretory effects in the colon and inhibition of gastrointestinal motility. We chose PYY as an index of the intrinsic factor in diarrhea and examined the influence of changes induced in a diarrhea rat model by administration of 4 types of laxative and loperamide hydrochloride (loperamide) as an agent for the treatment of diarrhea. A specific radioimmunoassay was performed to determine plasma and intestinal mucosal PYY concentrations. PYY in the rat intestinal tissue extract was distributed at a high density in the lower intestinal mucosa. In the diarrhea rat model, multiple changes in PYY concentrations in the intestinal mucosa and plasma were observed. In rats administered castor oil and sodium picosulfate, the intestinal mucosal PYY levels significantly decreased in a dose-dependent manner. Plasma PYY levels significantly decreased only in rats administered magnesium citrate. Next, we examined the influence of loperamide administration on the intestinal mucosa and plasma PYY concentrations in these rats. Loperamide administration resulted in multiple changes in plasma and intestinal mucosa PYY concentrations, along with an improvement in the diarrhea. Our research showed that the endocrine hormone PYY is involved in the onset of diarrhea, the course of the condition, and the manifestation of medicinal effects in the lower intestine.


Subject(s)
Antidiarrheals/pharmacology , Antidiarrheals/therapeutic use , Diarrhea/drug therapy , Diarrhea/metabolism , Loperamide/pharmacology , Loperamide/therapeutic use , Peptide YY/metabolism , Animals , Diarrhea/etiology , Disease Models, Animal , Dose-Response Relationship, Drug , Gastrointestinal Motility , Intestinal Mucosa , Peptide YY/blood , Peptide YY/physiology , Radioimmunoassay , Rats , Rats, Wistar
2.
Yakugaku Zasshi ; 128(9): 1347-53, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18758150

ABSTRACT

Few studies have reported the changes in the peptide YY (PYY) levels in the intestinal tissue of rats with ulcerative colitis (UC) following oral administration of mesalazine and prednisolone. We investigated the effects of these drugs on the intestinal mucosal PYY levels in a rat model of UC. We confirmed that the PYY levels in the rat intestinal mucosal tissue were high in the lower intestinal tract. The leukocyte count and hemoglobin levels approached the normal values after administering mesalazine or prednisolone to rats treated with 3% dextran sulfate sodium (DSS). The PYY levels in the caecum and colon decreased significantly after administering DSS but increased when mesalazine was administered in a tissue-specific manner. Unlike mesalazine, the PYY levels increased in the ileum in addition to the colon and rectum after administering prednisolone. However, neither of the drugs induced any changes in the plasma PYY levels. These findings indicate that changes in the intestinal tissue PYY levels may be partially involved in the improvement of DSS-induced UC in rats following the administration of these drugs.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Anti-Inflammatory Agents/pharmacology , Colitis, Ulcerative/metabolism , Intestinal Mucosa/metabolism , Mesalamine/pharmacology , Peptide YY/metabolism , Prednisolone/pharmacology , Administration, Oral , Animals , Anti-Inflammatory Agents/administration & dosage , Colitis, Ulcerative/chemically induced , Colitis, Ulcerative/drug therapy , Dextran Sulfate , Disease Models, Animal , Male , Mesalamine/administration & dosage , Prednisolone/administration & dosage , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...